<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03755245</url>
  </required_header>
  <id_info>
    <org_study_id>T282/2018</org_study_id>
    <nct_id>NCT03755245</nct_id>
  </id_info>
  <brief_title>Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis</brief_title>
  <acronym>SIGLEC</acronym>
  <official_title>PET/CT Study of Biodistribution and Performance of the [68Ga]Ga-DOTA-Siglec-9 in Patients With Rheumatoid Arthritis, and Radiation Dosimetry, Pharmacokinetics, Biodistribution, Safety and Tolerability in Healthy Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates safety, tolerability, biodistribution and performance of the
      [68Ga]Ga-DOTA-Siglec-9 following a single intravenous administration in patients with active
      rheumatoid arthritis, as well as radiation dosimetry, plasma pharmacokinetics,
      biodistribution, safety and tolerability of the tracer in healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vascular adhesion protein 1 (VAP-1) is an inflammation inducible endothelial cell molecule
      mediating leukocyte trafficking from blood into the sites of inflammation. Although VAP-1
      plays important role in early phases of inflammation, its luminal expression on the
      endothelium will remain constant if the inflammation continues, which suggest VAP-1 as a
      promising target for molecular imaging of inflammation. We have previously shown that sialic
      acid-binding immunoglobulin-like lectin 9 (Siglec-9) is a VAP-1 ligand, and the gallium-68
      labeled 1,4,7,10-tetraazacyclododecane-N,N´,N´´,N´´´-tetraacetic acid conjugated peptide
      ([68Ga]Ga-DOTA-Siglec-9) containing residues 283-297 from Siglec-9 can be used for PET
      imaging of inflammation in various experimental models. This first-in-human study evaluates
      safety, tolerability, biodistribution and performance of [68Ga]Ga-DOTA-Siglec-9 after single
      intravenous injection in six healthy volunteers and in ten patients with early rheumatoid
      arthritis (RA). VAP-1 is abundantly expressed in synovial blood vessel in RA joints, which is
      why they were selected as the first patient population.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 23, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Whole-body distribution, plasma pharmacokinetics, radiation dosimetry, safety, tolerability and performance of [68Ga]Ga-DOTA-Siglec-9</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Whole-body distribution of [68Ga]Ga-DOTA-Siglec-9</measure>
    <time_frame>within a day</time_frame>
    <description>Knowledge how intravenously injected [68Ga]Ga-DOTA-Siglec-9 is distributed in human body</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiation dosimetry of [68Ga]Ga-DOTA-Siglec-9</measure>
    <time_frame>within a week</time_frame>
    <description>Absorbed ionisation radiation dose in critical organs due to single intravenous 140 megabecquerel injection of [68Ga]Ga-DOTA-Siglec-9</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>[68Ga]Ga-DOTA-Siglec-9</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intravenous 140 MBq bolus injection of [68Ga]Ga-DOTA-Siglec-9 radiopharmaceutical</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[68Ga]Ga-DOTA-Siglec-9</intervention_name>
    <description>Vascular Adhesion Protein 1 (VAP-1) targeted radiopharmaceutical</description>
    <arm_group_label>[68Ga]Ga-DOTA-Siglec-9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy 18-70 year-old men

          -  Male or female 18-70 year-old patients with active rheumatoid arthritis

        Exclusion Criteria:

          -  In healthy: ongoing infection/inflammation proven by blood or other tests

          -  In patients with rheumatoid arthritis: no treatment with disease-modifying
             anti-rheumatic drugs or biologic agents, and no corticosteroids for 2 weeks prior the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Roivainen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital, Turku PET Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Turku University Hospital, Turku PET Centre</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 23, 2018</study_first_submitted>
  <study_first_submitted_qc>November 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>November 23, 2018</last_update_submitted>
  <last_update_submitted_qc>November 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Anne Roivainen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

